Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

EU drugs agency sets up Zika task force to speed vaccine work

Published 08/02/2016, 11:45
Updated 08/02/2016, 11:50
© Reuters. An employee examines tubes with the label 'Zika virus' at Genekam Biotechnology AG in Duisburg
SASY
-

LONDON (Reuters) - Europe's drugs regulator said on Monday it had established an expert task force on Zika to advise companies working on vaccines and medicines against the virus, which is suspected of causing a spike in birth defects in Brazil.

With no currently approved vaccines or medicines and none even undergoing clinical studies, the move by the London-based European Medicines Agency (EMA) is designed to ensure Zika development work proceeds as rapidly as possible.

"The agency is encouraging medicines developers to contact EMA if they have any promising projects in this area. EMA will also proactively reach out to companies already planning to work on investigational vaccines and offer scientific and regulatory advice," it said in a statement.

"Early and regular interaction with the agency can significantly speed up the development of medicines."

Several biotech and pharmaceutical companies are racing to develop a Zika vaccine, including France's Sanofi (PA:SASY), which already has vaccine for the similar condition of dengue.

© Reuters. An employee examines tubes with the label 'Zika virus' at Genekam Biotechnology AG in Duisburg

But scientists know relatively little about Zika and the road to developing a preventative shot against the mosquito-borne disease is strewn with hurdles.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.